Welcome to our dedicated page for Neogen SEC filings (Ticker: NEOG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Food safety diagnostics might feel far from Wall Street, yet Neogen’s supply-chain complexity shows up in hundreds of pages of disclosures. Tracking which genomic test kit drives revenue, or when management sells shares, is difficult. That’s why investors hunting for “Neogen insider trading Form 4 transactions” or the latest “Neogen quarterly earnings report 10-Q filing” often lose hours scrolling through EDGAR.
Stock Titan fixes this. Our AI reads every 10-K, 10-Q, 8-K and proxy the moment it is released, pushes “Neogen Form 4 insider transactions real-time” to your dashboard, and offers “Neogen SEC filings explained simply” with crisp language and data visualizations. Within seconds you’ll see a “Neogen earnings report filing analysis,” flagging segment sales for food safety, animal safety and genomics, plus cash flow shifts tied to acquisitions. Interactive links jump you straight to risk factors, while sidebars answer “understanding Neogen SEC documents with AI” without legalese.
Want specifics? The “Neogen annual report 10-K simplified” highlights R&D spend on LAMP molecular assays and global compliance costs. The “Neogen proxy statement executive compensation” module benchmarks pay packages against peer diagnostics firms. Alerts on “Neogen executive stock transactions Form 4” reveal buying patterns before material announcements, and our dashboard keeps the “Neogen 8-K material events explained” in plain sight when recalls or mergers hit. Whether you compare quarter-over-quarter allergen test kit sales, monitor insider sentiment, or review governance votes, Stock Titan delivers the intelligence you need, updated in real time and ready for decision making.
Neogen Corporation (NEOG) reported an insider transaction by a director. On 10/24/2025, the director acquired 19,386 shares of common stock at a $6.19 price and now holds 19,386 shares directly.
The filing also reports a grant of 49,929 stock options with a $6.19 exercise price, expiring on 10/24/2035. The options and RSUs vest in equal annual installments on each of the first three anniversary dates of the grants.
Neogen Corp (NEOG) filed a Form 3 for a reporting person serving as a Director. The filing states that no securities are beneficially owned. The event date is 10/24/2025, and the form was filed by one reporting person. The document is signed by Attorney in Fact Christopher Sefcheck on 10/28/2025.
Neogen Corp (NEOG) Form 4: A company director reported transactions dated 10/23/2025. The filer acquired 19,769 shares of common stock at $6.07, bringing directly held shares to 35,084 after the transaction. The filing indicates direct ownership.
The director was also awarded options covering 50,814 shares at an exercise price of $6.07, expiring 10/23/2035. According to the footnote, options and RSUs vest in equal annual installments on each of the first three anniversaries of the grant.
Neogen Corp (NEOG) — Form 4 insider report: A company director reported acquiring 19,769 shares of common stock on 10/23/2025 at $6.07 per share, bringing direct beneficial ownership to 19,769 shares. The filer also received a grant of options for 50,814 shares at a $6.07 exercise price, expiring 10/23/2035. Per the footnote, these awards vest in equal annual installments on each of the first three anniversaries of the grant date.
Neogen (NEOG) filed a Form 4 reporting director equity awards. On 10/23/2025, the reporting person acquired 19,769 shares of common stock at $6.07. Following this, directly held common stock totaled 36,788 shares.
The filing also reports 50,814 stock options granted at an exercise price of $6.07, expiring on 10/23/2035, with 50,814 derivative securities beneficially owned after the transaction. Per the footnote, options and RSUs vest in equal annual installments on each of the first three anniversary dates of the grants.
Neogen Corporation (NEOG) director reported equity grants. On 10/23/2025, the insider acquired 19,769 shares of common stock at $6.07 per share, bringing direct beneficial ownership to 43,757 shares. The filer also reported a grant of options to buy 50,814 shares at an exercise price of $6.07, expiring on 10/23/2035. According to the footnote, the options and RSUs vest in equal annual installments on each of the first three anniversaries of the grant date.
Neogen Corp (NEOG) reported an insider equity transaction. A director acquired 19,769 shares of common stock at $6.07 on 10/23/2025 (Transaction Code A). Following this, the director beneficially owned 34,621 common shares directly.
The filing also reports a grant of options to purchase 50,814 shares at an exercise price of $6.07, expiring on 10/23/2035. After the transactions, the director held 50,814 options. The options and RSUs vest in equal annual installments on each of the first three anniversary dates of the grants.
Neogen Corp (NEOG) — Form 4 insider report: A director reported an award on 10/23/2025. The filing shows 19,769 shares of common stock acquired (Code A) at $6.07, bringing direct beneficial ownership to 48,469 shares. The director was also granted options to purchase 50,814 shares at an exercise price of $6.07, expiring 10/23/2035. A footnote states the options and RSUs vest in equal annual installments on each of the first three anniversary dates of the grants.
Neogen Corp (NEOG) — Form 4 insider activity: A director reported awards dated 10/23/2025. The filing shows an acquisition of 19,769 shares of common stock and a grant of options covering 50,814 shares with a $6.07 exercise price, expiring on 10/23/2035. The form lists 19,769 common shares and 50,814 derivative securities beneficially owned following the transactions, all held directly. Both the options and RSUs vest in equal annual installments on each of the first three anniversaries of the grants.
Neogen (NEOG) reported an insider equity grant by a director on 10/23/2025. The filing shows 50,814 stock options with a $6.07 exercise price expiring on 10/23/2035, and 19,769 shares acquired.
Per the footnote, the options and RSUs vest in equal annual installments on each of the first three anniversary dates of the grants. Following these transactions, the director beneficially owned 112,314 shares, held directly.
FAQ
What is the current stock price of Neogen (NEOG)?
What is the market cap of Neogen (NEOG)?
